Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
ISTH Congress - International Society on Thrombosis and Haemostasis Congress
ISTH 2025: Abelacimab Demonstrates Low Periprocedural Bleeding Rates in Phase 2 Trial
Jeffrey I. Weitz, OC, MD, FAHA, FRCPC, FACP, FRSC, FACC, FESC, FCAHS;Alana Hippensteele, Lead Editor
July 28th 2025Jeffrey I. Weitz, OC, MD, FAHA, FRCPC, FACP, FRSC, FACC, FESC, FCAHS, discusses AZALEA-TIMI 71 trial data showing that the long-acting factor XI inhibitor abelacimab is associated with low periprocedural bleeding risk, supporting potential simplification of anticoagulation protocols for most elective and some urgent procedures.
